3D Printing Hydroxyapatite ink

Hazard statements (CLP)

H315, H319, H336, H351, H360Df

Code

Statements

H315

Causes skin irritation

SECTION 2: Hazards identification

Labelling according Regulation (EC) No 1272/2008 as amended by GB-CLP Classification of the substance or mixture

Signal word

Danger Danger

Hazard statements

H315 Causes skin irritation. H319 Causes serious eye irritation. H336 May cause drowsiness or dizziness. H351 Suspected of causing cancer. H360Df May damage the unborn child. Suspected of damaging fertility. EUH380 May cause endocrine disruption in humans. EUH430 May cause endocrine disruption in the environment. Restricted to professional users. Reduced Labelling (<= 125 ml) H351 Suspected of causing cancer. EUH380 May cause endocrine disruption in humans. EUH430 May cause endocrine disruption in the environment. H360Df May damage the unborn child. Suspected of damaging fertility.

Precautionary statements

P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P263 Avoid contact during pregnancy and while nursing. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P391 Collect spillage. P405 Store locked up. P501 Dispose of contents/ container to an approved waste disposal plant. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P263 Avoid contact during pregnancy and while nursing. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P391 Collect spillage. P405 Store locked up. P501 Dispose of contents/ container to an approved waste disposal plant.

Supplemental label elements

none none

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

ECOLOGICAL INFORMATION

This substance/mixture contains components considered to have endocrine disrupting properties for environment , according to REACH Article 57(f), Commission Regulation (EU) 2018/605 or Commission Delegated Regulation (EU) 2017/2100.

TOXICOLOGICAL INFORMATION

This substance/mixture contains components considered to have endocrine disrupting properties affecting human health, according to REACH Article 57(f), Commission Regulation (EU) 2018/605 or Commission Delegated Regulation (EU) 2017/2100.

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008 as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567 Skin irritation, (Category 2) H315: Causes skin irritation. Eye irritation, (Category 2) H319: Causes serious eye irritation. Carcinogenicity, (Category 2) H351: Suspected of causing cancer. Reproductive toxicity, (Category H360Df: May damage the unborn child. 1B) Suspected of damaging fertility. Specific target organ toxicity - H336: May cause drowsiness or dizziness. single exposure, (Category 3), Central nervous system Endocrine disruptor for human EUH380: May cause endocrine disruption in health, (Category 1) humans. Endocrine disruptor for EUH430: May cause endocrine disruption in environment, (Category 1) the environment.